Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



02 AUG 14 AM 9: 34

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

00 20036 5. Senate ID # 41454-583 6. House ID # 30771075 Ty 1-June 30) ☑ OR Year End (July 1-Dec	
41454-583 6. House ID # 30771075 Ty 1-June 30) OR Year End (July 1-Dec	
41454-583 6. House ID # 30771075 Ty 1-June 30) OR Year End (July 1-Dec	
y 1-June 30) ☒ OR Year End (July 1-Dec	
11. No Lobby 12 OR Line 13	
13. Organizations	
PENSES relating to lobbying activities for this report of were:	
than \$10,000 $\ \square$	
S10,000 or more Expenses (nearest \$20 14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of Method A. Reporting amounts using LDA definiti Method B. Reporting amounts under section 6033 the Internal Revenue Code	
Method C. Reporting amounts under section 162(Internal Revenue Code	
,]]	

Filing #0238f9b3-0ce7-4633-ba54-f453b9e51bd7 - Page 1 of 4

Registrant Name: Novartis. Inc. Client Name: Novartis. Inc. LOBRYTNG ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed. 15. General issue area code PHA (one per page) 16. Specific Lobbying issues Medicare payment for drugs Medical Privacy HIPAA final rule Medicare reform Payment for drugs Medical Privacy HIPAA final rule Medicare reform Pediatric exclusitivity Legislation to reform Hatch/Waxman Act 17. House(s) of Congress and Federal agencies contacted House of Representatives Senate Food & Drug Administration White House 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J. 19. Interest of each foreign entity in the specific issuey listed on line 16 above Check if None Signature Date \$114/02	**		00020270208
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed. 15. General issue area code PHA (one per page) 16. Specific Lobbying issues Medicar Privacy HPAA final rule Medicare reform Pediatric exclusitivity Legislation to reform Hatch/Waxman Act 17. House(s) of Congress and Federal agencies contacted House of Representatives Senate Food & Drug Administration White House 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J.	Registrant Name:	Williams & Jensen, PC	
engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed. 15. General issue area code PHA (one per page) 16. Specific Lobbying issues Medicare payment for drugs Medicar Privacy HIPAA final rule Medicare reform Pediatric exclusitivity Legislation to reform Hatch/Waxman Act 17. House(s) of Congress and Federal agencies contacted House of Representatives Senate Food & Drug Administration White House 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J.	Client Name:	Novartis, Inc.	
Medicare payment for drugs Medicare payment for drugs Medicare reform Pediatric exclusitivity Legislation to reform Hatch/Waxman Act 17. House(s) of Congress and Federal agencies contacted House of Representatives Senate Food & Drug Administration White House 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J.	engaged in lobbyi	ng on behalf of the client during the reporti	ing period. Using a separate page for each code, provide
Medicar payment for drugs Medicar privacy HIPAA final rule Medicare reform Pediatric exclusitivity Legislation to reform Hatch/Waxman Act 17. House(s) of Congress and Federal agencies contacted House of Representatives Senate Food & Drug Administration White House 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J. 19. Interest of each foreign entity in the specific issues listed on line 16 above	15. General issue	e area code PHA (one per page)	
House of Representatives Senate Food & Drug Administration White House 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J. 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None	Medicare pa Medical Pri Medicare re Pediatric ex	nyment for drugs vacy HIPAA final rule form clusitivity	
Name Covered Official Position (if applicable) Lynch, Karina V. Olsen, George G. Rosenkoetter, Thomas J. 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None	House of Re Senate Food & Dru	presentatives g Administration	☐ Check if None
Olsen, George G. Rosenkoetter, Thomas J. 19. Interest of each foreign entity in the specific issues listed on line 16 above		h individual who acted as a lobbyist in this	1
Rosenkoetter, Thomas J. 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None	Lynch, Kari	na V.	
19. Interest of each foreign entity in the specific issues listed on line 16 above ✓ Check if None	Olsen, Geor	ge G.	
	Rosenkoette	r, Thomas J.	
Signature Date <u>8/14/02</u>	19. Interest of ea	ch foreign entity in the specific issues liste	d on line 16 above 🛮 🗷 Check if None
	Signature		Date 8/14/02